South & Central America Colorectal Cancer Market

The colorectal cancer market in South & Central America is expected to grow from US$ 681.70 million in 2022 to US$ 814.50 million by 2028; it is estimated to grow at a CAGR of 2.2% from 2022 to 2028.

The market for colorectal cancer in the region is expected to grow owing to rise in the incidences of colorectal cancer and increase in the demand for colonoscopy procedures in Brazil. The market is also attributed to grow in Argentina due to the rising advancement for the technology to prevent incidences of the cancers.

The Rest of South & Central America colorectal cancer market is segmented into Chile, Peru, Ecuador, and other countries. According to GLOBOCAN 2020 data, there were approximately 6,219 new colorectal cancer cases in Chile, representing 11.5% of all new cancer cases in both genders, and ~4,636 new colorectal cancer cases were diagnosed in all ages in Peru.

Moreover, the majority of the countries in Latin America lack adequate systematic screening or prevention programs. The general screening of people aged above 50 years is a cost-effective and efficacious way of reducing colorectal cancer. Several South & Central American countries have developed national guidelines for early detection, management, and follow-up of colorectal cancer. Further, Uruguay has implemented colorectal cancer screening programs, while Chile, Cuba, and Ecuador have initiated pilot studies.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the South & Central America colorectal cancer market at a substantial CAGR during the forecast period.

 South & Central America Colorectal Cancer Market Revenue and Forecast to 2028 (US$ Million)

South & Central America Colorectal Cancer Strategic Insights

Strategic insights for the South & Central America Colorectal Cancer provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

South & Central America Colorectal Cancer Report Scope

South & Central America Colorectal Cancer Regional Insights

The geographic scope of the South & Central America Colorectal Cancer refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

South & Central America Colorectal Cancer Market Segmentation

The South & Central America colorectal cancer market is segmented into modality, and end user, and country. Based on modality, the global colorectal cancer market is segmented into diagnosis type, therapy type, and imaging type. In 2022, the diagnosis type segment holds the largest market share and is expected to register the highest CAGR during the forecast period. Based on end user, the global colorectal cancer market is bifurcated into hospitals and diagnostic & research laboratories. In 2022, the hospitals segment holds a larger market share. Based on country, the South & Central America colorectal cancer market is segmented into Brazil, Argentina, and the Rest of South & Central America. The Rest of South & Central America held the largest market share in 2022.

Abbott, Amgen Inc., Bruker Corporation, Clinical Genomics Technologies Pty Ltd., EDP Biotech Corporation, Epigenomics AG, F. Hoffmann-La Roche AG, Quest Diagnostics, and VolitionRx Limited are among the leading companies operating in the South & Central America colorectal cancer market.